In response to immune checkpoint blockade therapy, responsiveness to low ERLIN2 expression was higher in the TCGA-PARD cohort (Fig. 4F, G); responsiveness to low CDK5RAP3 expression was higher in the ICGA-PRAD cohort (Fig. 4F, G). This evidence concerns the gene CDK5RAP3 and prostate adenocarcinoma.